With 54 new drugs and seven cellular and gene therapy products, the approvals by the US Food and Drug Administration (FDA) recovered 2023 from the 2022 dent back to the levels of 2020–2021. As in previous years of this annual review, we assign these new drugs to one of three levels o...
TCRT,CAR-NK,tumor-infiltrating lymphocyte (TIL), andstem cells.These nascent therapies have shown encouraging progress. Most notably, the first cell therapy for type 1 diabetes (Latindra) received FDA approval in 2023; the first TIL (Lifileucel), in 2024; and the first TCR-T therapy has ...
new biological products, gene and cell therapies, new vaccines, and new traditional Chinese medicines approved for the first time in mainland China. Chemical drugs accounted for the largest proportion of new drug approvals (72, or 69.2
Nature Reviews Drug Discovery volume 23, pages 682–708 (2024)Cite this article 7400 Accesses 14 Altmetric Metrics details Abstract Epilepsy is a common brain disorder, characterized by spontaneous recurrent seizures, with associated neuropsychiatric and cognitive comorbidities and increased mortality. ...
Vorasidenib has been approved by the U.S. Food and Drug Administration (FDA) for patients with Grade 2 gliomas with IDH1 or IDH2 mutations. Based on evidence from the INDIGO clinical trial, a global phase 3, double-blinded, randomized clinical trial, vorasidenib more than doubled...
2022 drug approvals: After Aduhelm fiasco, FDA endorsements drop to 37 On the flip side, the FDArejectedEli Lilly’s touted Alzheimer’s treatment donanemab. But the company appears to be on track for approval in 2024. Other big winners in ’23 ...
In clinical trials, AbbVie's risankizumab-rzaa produced high rates of durable skin clearance – most people (82 and 81%) treated with the drug achieved 90% skin clearance (PASI 90) at 1 year, with the majority (56 and 60%) achieving complete skin clearan
Functional bowel disorders (FBDs) are a spectrum of disorders characterized by combinations of symptoms attributable to the lower gastrointestinal tract. Most current first-line therapies for IBS and other FBDs target the predominant symptom and mainly a
The US FDA New Drug Approvals in December 2024 January 14, 2025 PharmaShots’ Key Highlights of Fourth Quarter 2024 January 13, 2025 J.P. Morgan Healthcare Conference Special: Dealmaker of the Year 2024 (Part 01) January 8, 2025 Key Biosimilars Events of December 2024 January 7, 20...
SophiaJanuary 23, 2025 In 2024, China's pharmaceutical field thrived. NMPA approved 220 new drugs, including 46 Class 1 innovative ones with anti-tumor drugs being the most. New anti-tumor drugs offered hope, and the R&D environment will keep improving....